Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Multiple Myeloma Treatment Market $20 Billion by 2027

The global market for multiple myeloma treatment anticipated to reach $20 billion by 2027, growing slowly at a CAGR of 0.1% over the forecast period, driven by patent expiry of premium-priced branded drugs, introduction of generic products, and potential approval of novel therapies.

  • Factors contributing the market growth includes long treatment durations and prolonged survival rates. The sales of multiple myeloma drugs are among the highest in North America, owing to the availability of premium-priced branded agents prescribed in doublet and triplet regimens in the United States.
    • However, the global market for multiple myeloma branded drugs expected to decline post 2025, due to generic erosion of immunomodulators (lenalidomide, pomalidomide, thalidomide), proteasome inhibitors (bortezomib, carfilzomib), histone deacetylase inhibitor (panobinostat), and alkylating agents (bendamustine).
Global Multiple Myeloma Treatment Market

Multiple myeloma (MM) is considered the second most common blood cancer, with about 160,000 new cases diagnosed globally per year. Multiple myeloma accounts for just over 10 percent of all blood cancers (hematologic cancer).

  • According to the National Cancer Institute, statistics on multiple myeloma include 30,770 estimated new cases of myeloma occurred in the United States in 2018. In addition, 1.8 percent of all new cancer cases in the United States involve myeloma.

The global multiple myeloma therapeutics market report provides market size (Revenue US$ million 2017 to 2027), market share, growth trends and forecast (CAGR%, 2021 to 2027).

The global market for multiple myeloma drugs segmented by product (drug class/brand/generic) – immunomodulatory agents [Revlimid (lenalidomide), generic lenalidomide, Pomalyst (pomalidomide), generic pomalidomide, Thalomid (thalidomide), generic thalidomide], proteasome inhibitors [Velcade (bortezomib), generic bortezomib, Kyprolis (carfilzomib), generic carfilzomib, Ninlaro (ixazomib)], monoclonal antibodies / cell-surface-targeted agents [Darzalex (daratumumab), Empliciti (elotuzumab), Sarclisa (isatuximab)], apoptosis-inducing agents [Venclexta (venetoclax)], nuclear export inhibitor / selective inhibitors of nuclear export [Xpovio (selinexor)], B-cell maturation antigens [Abecma (idecabtagene vicleucel / ide-cel), Blenrep (belantamab mafodotin)], histone deacetylase inhibitors [Farydak (panobinostat), generic panobinostat, alkylating agents [Treanda (bendamustine), Bendeka (bendamustine), genenric bendamustine, Ygalo (melphalan-flufenamide)], and geography.

The main approaches to multiple myeloma treatment include chemotherapy, non-chemotherapy, corticosteroids and stem cell transplantation. However, in the past decade, there have been extraordinary advances in the treatment. New drugs for multiple myeloma have transformed treatment and agents in the pipeline promise further advances.

  • Based on the drug classes, the immunomodulators segment accounted for the largest share of the MM treatment market, whereas the nuclear export inhibitor / selective inhibitors of nuclear export [Xpovio (selinexor)] and apoptosis-inducing Agents (BCL-2 Inhibitor), and the B-cell maturation antigens / (BCMA)- targeted CAR-T therapy segments anticipated to witness the fastest double-digit growth rate over the forecast period.
    • With the advent of novel therapies such as thalidomide, lenalidomide, and bortezomib, overall survival in myeloma patients has significantly improved.
      • Unfortunately, however, this improvement was predominantly found in patients under 60–75 years of age. As long-term oral treatment for multiple myeloma is growing, strategies to manage and prevent treatment-related toxicities are a major concern.
        • Patient education approaches have been developed, to increase self-care knowledge and skills, enabling autonomy in self-administration of medication.
    • There are at least seven bispecific monoclonal antibodies in the race to reach the relapsed or refractory multiple myeloma market.
      • The bispecific monoclonal antibodies may take a bite out of CAR-T cell therapy market due to the former’s off-the-shelf convenience.
  • Celgene’s immunomodulatory agent Revlimid (lenalidomide) is the top-selling drug approved for multiple myeloma and estimated to remain a blockbuster over the forecast period.
    • Revlimid, Takeda Pharmaceutical Company Ltd.’s proteasome inhibitors Ninlaro (ixazomib) and Velcade (bortezomib), as well as Amgen/Ono Pharmaceutical’s proteasome inhibitor Kyprolis (carfilzomib) have become cornerstone therapies in treating multiple myeloma.
      • Amgen/Ono Pharmaceutical’s Kyprolis (carfilzomib) and Takeda Pharmaceutical Company Ltd.’s Ninlaro (ixazomib) are both approved for relapsed or refractory (R/R) multiple myeloma. Celgene’s third-generation immunomodulatory agent Pomalyst/Imnovid (pomalidomide) has been approved for R/R multiple myeloma.
  • Most monoclonal antibody drugs, including Johnson & Johnson’s Darzalex, Sanofi’s Sarclisa (isatuximab), and Bristol-Myers Squibb’s Empliciti (elotuzumab) are being positioned in combination with existing therapies, including Revlimid, Velcade and dexamethasone.
    • Two monoclonal antibodies [Empliciti (elotuzumab) and Darzalex (daratumumab)] that target cell-surface antigens are approved to treat multiple myeloma.

The global multiple myeloma treatment market research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

  • In terms of geographic distribution, the North America region accounted for the largest share of the multiple myeloma drugs market, followed by the Europe region and expected to maintain its leadership position during the forecast period.
    • According to the National Cancer Institute’s (NCI) statistics on multiple myeloma include 30,770 estimated new cases of myeloma occurred in the United States in 2018 at a median age at diagnosis of 69 years.
    • According to the American Cancer Society’s (ACS) estimates for multiple myeloma about 32,210 new cases were diagnosed in United States for 2020, , corresponding to 1.8% of all new cancer cases.
      • It is not a common cancer but is the second most common blood cancer after non-Hodgkin lymphoma in the United States.
  • The global burden of multiple myeloma has increased uniformly in the last 30 years, but the incidence of myeloma is highly variable among different countries. Multiple myeloma is a hematologic malignancy predominately affecting older adults. Despite significant treatment advances in recent years, this disorder still remains incurable.
    • The estimated world-wide 5-year prevalence is approximately 230,000 patients. Incident cases will increase substantially over the forecast period.
      • According to WHO, multiple myeloma is expected to be more prominent in the developed world due to aging population, family history, and exposure to certain chemicals and drugs.

The global multiple myeloma drugs market report also provides the detailed market landscape (market drivers, restraints, and opportunities), market attractiveness analysis and tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.

Major competitors operating in the global market for multiple myeloma therapeutics market and profiled in this report include AbbVie, Inc., Amgen, inc., Autolus Therapeutics, Inc., bluebird bio, Inc., Bristol-Myers Squibb Company (Celgene Corporation), GlaxoSmithKline plc, ImmunoGen, Inc., Johnson & Johnson (Janssen), Karyopharm Therapeutics, Inc., Legend Biotech Corporation (Genscript Biotech), Novartis AG, Oncopeptides AB, Ono Pharmaceutical Co., Ltd., Poseida Therapeutics, Inc., Roche Holding AG (F. Hoffmann-La Roche AG), Sanofi S.A., Takeda Pharmaceutical Company Ltd., and Teva Pharmaceuticals Industries Ltd.

  • Drug Class (Product/Brand/Generic)
    • Immunomodulatory Agents (IMiD)
      • Revlimid (lenalidomide)
      • Generic Lenalidomide
      • Pomalyst (lomalidomide)
      • Generic Lomalidomide
      • Thalomid (thalidomide)
      • Generic Thalidomide
    • Proteasome Inhibitors (PIs)
      • Velcade (bortezomib)
      • Generic Bortezomib
      • Kyprolis (carfilzomib)
      • Generic Carfilzomib
      • Ninlaro (ixazomib)
    • Monoclonal Antibodies (MAb) / Cell-Surface-targeted Agents (CD38 / SLAMF7)
      • Darzalex (daratumumab)
      • Empliciti (elotuzumab)
      • Sarclisa (isatuximab)
    • Apoptosis-inducing Agents (BCL-2 Inhibitor)
      • Venclexta (venetoclax)
    • Nuclear Export Inhibitor / Selective Inhibitors of Nuclear Export (SINE) / XPO1 Inhibitor
      • Xpovio (selinexor)
    • B-cell Maturation Antigens (BCMA) / BCMA-targeted Agents / CAR-T
      • Abecma (idecabtagene vicleucel / ide-cel)
      • Blenrep (belantamab mafodotin)
    • Histone Deacetylase (HDAC) Inhibitors
      • Farydak (panobinostat)
      • Generic Panobinostat
    • Alkylating Agents
      • Treanda (bendamustine)
      • Bendeka (bendamustine)
      • Generic Bendamustine
      • Ygalo (melphalan flufenamide)
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • AbbVie, Inc.
    • Amgen, Inc.
    • Autolus Therapeutics, Inc.
    • bluebird bio, Inc.
    • Bristol-Myers Squibb Company (Celgene Corporation)
    • GlaxoSmithKline plc
    • ImmunoGen, Inc.
    • Johnson & Johnson (Janssen)
    • Karyopharm Therapeutics, Inc.
    • Legend Biotech Corporation (Genscript Biotech)
    • Novartis AG
    • Oncopeptides AB
    • Ono Pharmaceutical Co., Ltd.
    • Poseida Therapeutics, Inc.
    • Roche Holding AG (F. Hoffmann-La Roche AG)
    • Sanofi S.A.
    • Teva Pharmaceuticals Industries Ltd.

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: [email protected]